Inmed Pharmaceuticals Inc lost $8.36 per diluted share in fiscal year 2025. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $2.11 per diluted share. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Inmed Pharmaceuticals Inc has filed alongside them.
FY2025 annual
EPS (Diluted)-$8.36
Source SEC Filings (10-K/10-Q)Latest period Q3 FY2026, ended Mar 31, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
INM EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Inmed Pharmaceuticals Inc's diluted earnings per share in fiscal year 2025?
Inmed Pharmaceuticals Inc lost $8.36 per diluted share in fiscal year 2025.
What is Inmed Pharmaceuticals Inc's diluted earnings per share over the last twelve months?
Inmed Pharmaceuticals Inc (INM) reported a loss of $2.11 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
What was Inmed Pharmaceuticals Inc's diluted earnings per share in the most recent quarter?
Inmed Pharmaceuticals Inc (INM) reported -$0.73 in diluted earnings per share in Q3 2026.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Inmed Pharmaceuticals Inc (INM) reported on that line in every period on record.
